2007 (30 Publikationen)

• Heiduschka P, Fietz H, Hofmeister S, Schultheiss S, Mack AF, Peters S, Ziemssen F, Niggemann B, Julien S, Bartz-Schmidt KU, Schraermeyer U; Tübingen Bevacizumab Study Group. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007; 48: 2814-2823 [IF 3.528]
• Rohrbach JM, Grüb M, Szurman P. Einseitige, rezidivierende Trübung des Hornhautepithels. Ophthalmologe 2007; 223: 72-74 [IF 0.791]
• Szurman P, Petermeier K, Grisanti S, Jaissle GB, Bartz-Schmidt KU. A new small-incision technique for injector implantation of transsclerally sutured foldable lenses. Ophthalmic Surg Lasers Imaging 2007; 38: 76-80 [IF 1.432]
• Lüke M, Krott R, Warga M, Szurman P, Grisanti S, Bartz-Schmidt KU, Schneider T, Lüke C. Effects of the protein tyrosine kinase inhibitor genistein and taurine on retinal function in isolated superfused retina. Graefes Arch Clin Exp Ophthalmol 2007; 245 : 242-248 [IF 1.59]
• Spitzer MS, Szurman P, Rohrbach JM, Aisenbrey S. Beidseitiges kongenitales Glaukom bei einem Kind mit Cutis marmorata telangiectatica congenita. Klin Monatsbl Augenheilkd 2007; 224: 66-69 [IF 0.576]
• Gekeler F, Szurman P, Grisanti S, Weiler U, Claus R, Greiner TO, Volker M, Kohler K, Zrenner E, Bartz-Schmidt KU. Compound subretinal prostheses with extra-ocular parts designed for human trials: successful long-term implantation in pigs. Graefes Arch Clin Exp Ophthalmol 2007; 245: 230-241 [IF 1.59]
• Jaissle GB, Szurman P, Völker M, Bartz-Schmidt KU. Epiretinal deposit of triamcinolone acetonide at the posterior pole after intravitreal injection. Ophthalmic Surg Lasers Imaging 2007; 38: 238-241 [IF 1.432]
• Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz-Schmidt KU; Tübingen Bevacizumab Study Group, Schraermeyer U. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007; 143: 995-1002 [IF 2.628]
• Spitzer MS, Szurman P, Aisenbrey S, Rohrbach JM. Rapid development of band keratopathy of corneal graft after treatment with intracameral recombinant tissue plasminogen activator for postoperative fibrin reaction. Eur J Ophthalmol 2007; 17: 433-436 [IF 1.018]
• Szurman P, Roters S, Grisanti S, Aisenbrey S, Rohrbach JM, Warga M, Gelisken F, Spitzer MS, Bartz-Schmidt KU. Primary silicone oil endotamponade in the management of severe intraocular foreign body injuries: an eight-year follow-up. Retina 2007; 27: 304-311 [IF 3.088]
• Szurman P, Kaczmarek R, Jaissle GB, Grisanti S, Lüke M, Spitzer MS, Heide PE, Bartz-Schmidt KU. Influence of different purification techniques on triamcinolone yield and particle size spectrum. Graefes Arch Clin Exp Ophthalmol 2007; 245: 689-696 [IF 1.59]
• Ziemssen F, Lüke M, Messias A, Beutel J, Tatar O, Zrenner E, Bartz-Schmidt KU; Tuebingen Bevacizumab Study Group. Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. Int Ophthalmol 2007; 28: 101-109 []
• Petermeier K, Szurman P. Subjektive und objektive Ergebnisse nach Implantation der apodisiert diffraktiven AcrySof ReSTOR. Ophthalmologe 2007; 104: 399-408 [IF 0.791]
• Tatar O, Adam A, Shinoda K, Yoeruek E, Szurman P, Bopp S, Eckardt C, Bartz-Schmidt KU, Grisanti S. Influence of Verteporfin Photodynamic Therapy on Inflammation in Human Choroidal Neovascular Membranes secondary to Age-Related Macular Degeneration. Retina 2007; 27: 713-723 [IF 3.088]
• Aisenbrey S, Bartz-Schmidt KU, Walter P, Hilgers RD, Ayertey H, Szurman P, Thumann G. Long-term follow-up of macular translocation with 360 degrees retinotomy for exudative age-related macular degeneration. Arch Ophthalmol 2007; 125: 1367-1372 [IF 2.984]
• Peters S, Altvater A, Bopp S, Vonthein R, Szurman P, Spitzer MS, Warga M, Lüke M, Bartz-Schmidt KU, Grisanti S. Systematic evaluation of ICG and Trypan Blue related effects on ARPE-19 cells in vitro. Exp Eye Res 2007; 85: 880-889 [IF 2.651]
• Spitzer MS, Sierra A, Yoeruek E, Wallenfels-Thilo B, Schraermeyer U, Spitzer B, Bartz-Schmidt KU, Szurman P. Comparative antiproliferative and cytotoxic profile of bevacizumab (AvastinTM), pegaptanib (MacugenTM) and ranibizumab (LucentisTM) on different ocular cells. Graefes Arch Clin Exp Ophthalmol 2007 ; 245 : 1837-1842 [IF 1.59]
• Szurman P, Sierra A, Kaczmarek R, Jaissle GB, Wallenfels-Thilo B, Grisanti S, Lüke M, Bartz-Schmidt KU, Spitzer MS. Different biocompatibility of crystalline triamcinolone deposits on retinal cells in vitro and in vivo. Exp Eye Res 2007, 85: 44-53 [IF 2.651]
• Yoeruek E, Spitzer MS, Tatar O, Aisenbrey S, Bartz-Schmidt KU, Szurman P. Safety profile of bevacizumab (Avastin®) on cultured human corneal cells. Cornea. 2007; 26: 977-982 [IF 1.776]
• Yoeruek E, Jaegle H, Lüke M, Grisanti S, Warga M, Krott R, Spitzer MS, Tatar O, Bartz-Schmidt KU, Szurman P. Safety profile of a taurine containing irrigation solution (AcriPurRet®) in pars plana vitrectomy. Retina 2007; 27: 1286-1291 [IF 3.088]
• Aisenbrey S, Ziemssen F, Völcker M, Gelisken F, Szurman P, Jaissle G, Grisanti S, Bartz-Schmidt KU. Intravitreal bevacizumab (Avastin) for occult choroidale neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007; 245: 941-948 [IF 1.59]
• Jaissle GB, Szurman P, Rohrbach JM, Gelisken F, Bartz-Schmidt KU. A case of cutaneous melanoma metastatic to the vitreous cavity: Possible pathomechanism and review of the literature. Graefes Arch Clin Exp Ophthalmol 2007; 245: 733-740 [IF 1.59]
• Heiligenhaus A, Szurman P, Heinz C. Aktuelle Kataraktchirurgie bei Uveitis im Kindesalter. Ophthalmologe 2007; 104: 572-576 [IF 0.791]
• Peters S, Julien S, Heiduschka P, Grisanti S, Ziemssen F, Adler M, Schraermeyer U, Bartz-Schmidt KU; The Tuebingen Bevacizumab Study Group. Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. Br J Ophthalmol 2007; 91: 827-831 [IF 2.689]
• Szurman P, Heiligenhaus A, Hettlich HJ, Dick HB, Kohnen T. Kataraktchirurgie bei Uveitis im Kindesalter. Klin Monatsbl Augenheilkd 2007; 224: 532-537 [IF 0.576]
• Aisenbrey S, Gelisken F, Szurman P, Bartz-Schmidt KU. Surgical treatment of peripapillary choroidal neovascularization. Br J Ophthalmol 2007; 91: 1027-1030 [IF 2.689]
• Beutel J, Greulich L, Lueke M, Ziemssen F, Szurman P, Bartz-Schmidt KU, Grisanti S. Inner Limiting Membrane as membranous support in RPE sheet-transplantation. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1469-1473 [IF 1.59]
• Lüke M, Januschowski K, Warga M, Beutel J, Leitritz M, Gelisken F, Grisanti S, Schneider T, Lüke C, Bartz-Schmidt KU. Szurman P. The retinal tolerance to bevacizumab in co-application with a recombinant tissue plasminogen activator. Br J Ophthalmol 2007; 91: 1077-1082 [IF 2.689]
• Gelisken F, Voelker M, Schwabe R, Besch D, Aisenbrey S, Szurman P, Grisanti S, Herzau V, Bartz-Schmidt KU. Full Macular Translocation versus Photodynamic Therapy with Verteporfin in Treatment of Neovascular Age-related Macular Degeneration: 1 Year Results of a prospective, controlled, randomised Pilot-Trial (FMT-PDT). Graefes Arch Clin Exp Ophthalmol 2007, 245: 1085-1095 [IF 1.59]
• Lüke M, Szurman P, Schneider T, Lüke C. Effects of the phosphodiesterase type V inhibitor sildenafil on human retinal function in vitro. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1211-1215 [IF 1.59]